Paradigm Spine said today it won coverage for its Coflex interlaminar stabilization device intended to treat lumbar spinal stenosis from AmeriHealth Caritas. The Coflex interlaminar stabilization system is the New York-based company’s flagship device, and is designed for posterior lumbar preservation in patients with moderate to severe spinal stenosis. With the coverage, an additional 5.3 […]
RTI Surgical (NSDQ:RTIX) agreed to put $300 million on the table for Paradigm Spine and its Coflex lumbar stenosis device. The cash-and-stock deal calls for Alachua, Fla.-based RTI to pay $100 million in cash and more than 10.7 million shares of its own stock worth $50 million, with the $150 million balance pegged to unspecified milestones in […]
BlueCross BlueShield of South Carolina has extended coverage to Paradigm Spine’s Coflex interlaminar stabilization implant, the company announced today. Approved by the FDA in 2012, Coflex is a non-fusion, motion-preserving stabilization implant for the treatment of lumbar spinal stenosis (LSS). Used in conjunction with a decompression procedure or in lieu of a spinal fusion, Coflex is a single-piece, […]
Paradigm Spine said today it won FDA premarket approval for its Coflex Interlaminar stabilization disposable instrument kit, touting it as the first FDA PMA-cleared disposable spinal instrument set for a Class III spinal device. The Coflex interlaminar stabilization system is the New York-based company’s flagship device, and is designed for posterior lumbar preservation in patients […]
Second Sight Medical (NSDQ:EYES) said last week it named John Blake as its new chief financial officer, succeeding Thomas Miller who has held the position since 2014. Before joining Second Sight Medical, Blake acted as finance senior VP at Tyr Pharma, and has held positions with Volcano Corp and BD Biosciences, the company said. Blake worked with […]
Paradigm Spine said it inked a $75 million credit agreement with PDL BioPharma.
Paradigm Spine, which makes spinal implants, said it will take the 1st $50 million in at closing, with another $25 million in milestone-based payments on the table.
Paradigm Spine won FDA approval for its Coflex spinal stenosis treatment system, the 1st such device to treat moderate to severe cases of spinal stenosis that may present with or without back pain.
Paradigm calls the Coflex device the "the 1st and only motion-preserving alternative to fusion for the treatment of moderate to severe spinal stenosis."
Outgoing Johnson & Johnson (NYSE:JNJ) CEO William Weldon will take home $143.5 million in retirement benefits when he walks in April.
The veteran J&J employee racked up more than $95 million in deferred compensation and $48.4 million in pension benefits over more than 40 years with the health care titan, according to an SEC filing.